Drug discovery company Evotec SE (Frankfurt Stock Exchange:EVT) said on Thursday that it has entered into a research collaboration with Indivumed GmbH to discover and develop first-in-class therapeutics for the treatment of non-small cell lung cancer (NSCLC).

Under the partnership, Evotec will combine its proprietary bioinformatics analysis platform 'PanHunter', as well as its small molecule and antibody discovery platforms, with the NSCLC cohort of Indivumed's true multi-omics cancer database 'IndivuType' and its advanced analytics and AI capabilities. The final goal is to deliver highly effective treatments for NSCLC patients.

This agreement follows the successful progress of the companies' previous joint drug discovery programme in the field of colorectal cancer which identified several novel drug targets that will be used in the development of new treatments for the disease.

Both parties will jointly invest in data analysis, target identification, validation and subsequent drug discovery. Evotec will be responsible for subsequent partnering of the programmes and the platform.

No financial details of the agreement were disclosed.